Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Transcode Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 13 | 1 | 18 | +6 |
| Shares | 2.06M | 6.50K | 345.2K | −1.71M (−83.2%) |
| Value | $2.27M | $7.00K | $222.5K | −$2.04M (−90.2%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (12)
Institutions that held Transcode Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cahill Wealth Management, LLC | 47,060 | $22.9K | 0.02% |
| HRT Financial LP | 25,995 | $17.0K | 0.00% |
| Sheets Smith Wealth Management | 25,000 | $16.8K | 0.00% |
| Susquehanna International Group, LLP | 20,854 | $14.0K | 0.00% |
| Two Sigma Investments, LP | 19,407 | $13.1K | 0.00% |
| Goldman Sachs Group Inc | 17,122 | $11.5K | 0.00% |
| Virtu Financial LLC | 16,361 | $11.0K | 0.00% |
| Renaissance Technologies LLC | 13,500 | $9.00K | 0.00% |
| Millennium Management LLC | 12,880 | $9.00K | 0.00% |
| Triumph Capital Management | 10,000 | $6.73K | 0.00% |
| Morgan Stanley | 1,165 | $784 | 0.00% |
| UBS Group AG | 1,159 | $777 | 0.00% |
Sold out (6)
Institutions that held Transcode Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| AIGH Capital Management LLC | 1,289,000 | $1.42M |
| Worth Venture Partners, LLC | 324,157 | $357.0K |
| Vanguard Group Inc | 200,117 | $220.0K |
| Redmond Asset Management, LLC | 90,874 | $100.0K |
| K.J. Harrison & Partners Inc | 19,987 | $22.0K |
| Royal Bank of Canada | 86 | $0 |
Not filed for Q4 2022 yet (1)
Institutions that held Transcode Therapeutics, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| ACT Capital Management, LLC | 6,500 | $7.00K |